Page 32 - உயிரி தொழில்நுட்பவியல் நிறுவனம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Zealand Pharma Virtual R&D Day Materials Now Available with Live Q&A Session on March 5, 2021
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Global Immunology Market : Top Companies , Size, Share, Industry Trend, Growth Rate & Forecast 2020-2027
texasguardian.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from texasguardian.com Daily Mail and Mail on Sunday newspapers.
Global Immunology Market : Top Companies , Size, Share, Industry Trend, Growth Rate & Forecast 2020-2027
sandiegosun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sandiegosun.com Daily Mail and Mail on Sunday newspapers.
DURHAM, N.C., March 02, 2021 (GLOBE NEWSWIRE) Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced management will participate in the following upcoming virtual investor conferences: H.C. Wainwright Global Life Sciences Conference Date: Tuesday, March 9, 2021 The fireside chat will be available on demand beginning at 7:00 AM ET with an archived replay available for 90 days. Barclays Global Healthcare Conference Date: Tuesday, March 9, 2021 Presentation: 10:55 AM ET An archived replay of this corporate presentation will be available for one year. Webcasts will be accessible on the Company’s website, www.precisionbiosciences.com, in the Investors & Media section under Events and Presentations. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving
kits and reagents segment dominated the market with its largest revenue share contribution, owing to
the increasing use of consumables for mycoplasma analysis while conducting cell culture research work and related activities.
In terms of technology, the
Polymerase Chain Reaction (PCR) segment held the majority of the market share and is expected to constitute more than half of the market over the forecast period.
High specificity, efficiency, and preciseness are some of the key attributes that make PCR ideal for mycoplasma analysis.
Pharmaceutical & biotechnology companies market segment accounted for over 25% of the
revenue share in 2019 owing to the growing demand for mycoplasma testing for cell culture research and several research & development activities